Trial Against Drugmaker Eli Lilly Delayed In Spartanburg Monday

Trial Against Drugmaker Eli Lilly Delayed In Spartanburg Monday

Eli Lilly

» 1 Comment | Post a Comment

**Monday 11:20am Update**

Mark Plowden, with the South Carolina Attorney General’s Office, says there will be no action in court Monday on the suit involving Eli Lilly. Plowden didn’t elaborate on the reasons for the delay.

A trial against a major drugmaker is scheduled to begin Monday in Spartanburg. The South Carolina Attorney General’s Office claims Eli Lilly failed to provide adequate warnings about the risks of taking the drug Zyprexa.

The suit claims the drug causes weight gain, which leads to diabetes, strokes, seizures, and other health problems. Prosecutors want Eli Lilly to pay restitution for all the money South Carolina has spent providing treatment to citizens through Medicaid and the state employees’ health plan.

No specific amount of money is specified. Eli Lilly denies all the allegations.

Advertisement

 
View More: zyprexa,spartanburg,south carolina,eli lilly,attorney general,
Not what you're looking for? Try our quick search:
 

Advertisement

Reader Reactions

Flag Comment Posted by Danny Haszard on October 05, 2009 at 4:45 am

Eli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.

Addictive Zyprexa was pushed by Lilly Drug Reps.
They called it the “Five at Five” (5 mg at 5 pm to keep nursing home patients subdued and sleepy) and “VIVA ZYPREXA” (Zyprexa for everybody) campaigns to off label market Eli Lilly Zyprexa as a fix for unapproved usage.

Eli Lilly is ‘reaping the whirlwind’ for aggressive marketing of Zyprexa that has caused suffering and deaths.
There must be millions out there harmed by this drug.

Daniel Haszard
  http://www.zyprexa-victims.com
Only 9 percent of adult Americans think the pharmaceutical industry can be trusted right around the same rating as big tobacco.

Post a Comment(Requires free registration)

The commenting period has ended or commenting has been deactivated for this article.

Advertisement

Advertisement

Advertisement

Advertisement